CMS expands access to COVID-19 antibody treatments for Medicare beneficiaries

Nov 11, 2020
The Bottom Line

The Food and Drug Administration issued an emergency use authorization (EUA) for the monoclonal antibody therapy bamlanivimab on November 9. As a result, Medicare beneficiaries will receive coverage of monoclonal antibodies to treat COVID-19 during the public health emergency, announced CMS administrator Seema Verma.

CMS anticipates that healthcare providers will initially receive the monoclonal antibody product at no charge. While Medicare will not be paying for the monoclonal antibody products, the action by CMS will provide reimbursement for the infusion of the product.

CMS will be releasing billing and coding instructions for providers in the coming days.

To view the Monoclonal Antibody COVID-19 Infusion Program Instruction, visit:

Quarterly Member Calls

Members-only calls

Enjoy upcoming and past Quarterly Calls with your AMBR Membership! Click here!

Access sample white papers, tools, analysis, and resources.

Featured Event

Tuesday, October 6, 2020 - 07:00

2019 Revenue Integrity Symposium

The 2020 Revenue Integrity Symposium covers topics essential to revenue integrity, Medicare compliance, and the revenue cycle in acute care and long-term care settings.